P95 BV, an Ampersand Capital Partners portfolio company, is proud to announce the appointment of Laurence De Moerlooze as Chief Medical Officer (CMO).

As we approach our 13th anniversary on June 16, we pause to celebrate important milestones and extend our deepest gratitude to our staff, partners and clients who have been part of our growth journey!

In a recent interview for Ampersand Capital Partners, our CEO, Thomas Verstraeten, and Chairman, Benoit Bouche shared pivotal insights into P95’s growth from an epidemiology consulting into a global comprehensive Contract Research Organization (CRO).

Almost one year from P95’s partnership with Ampersand Capital Partners, the article dives deeper into P95’s expanding global reach, client-focused capabilities, and commitment to global health that bring our company to the forefront.

We are excited to welcome John O’Brien as our new Chief Business Officer! John has a proven track record of driving commercial success and building strategic partnerships, bringing a wealth of experience to our team.

id.DRIVE is a Public-Private-Partnership, which consists of a unique consortium of pharmaceutical companies, public health institutes and research groups who are joining forces to monitor infectious diseases and effectiveness of related pharmaceutical products in real-life in Europe. This is achieved by several pharmaceutical companies co-funding a research network of hospitals.

Our P95 colleague Kaatje Bollaerts is excited to announce that the book ‘Vaccination Programmes | Epidemiology, Monitoring, Evaluation’ by Susan Hahné, Kaatje Bollaerts, and Paddy Farrington is now available to all to view and use online through a new open-access grant provided by CEPI.

As actions speak louder than words, from an internal fundraising initiative, P95 made multiple donations in 2023 that will help charities across the globe.

Healthcare analytics provider LOGEX and P95, a company specialized in epidemiology of infectious diseases, have signed...

Almost two years after expanding its operations to Latin America with the creation of P95 Latina, our company has...

At the beginning of October, we held our Annual Retreat in beautiful Mallorca. Around 100 employees were present! This...

We're excited to share a quick tour of our new P95 Latina office in Bogotá, Colombia, which opened in August 2022. The...

After five years, the Development of Robust and Innovative Effectiveness (DRIVE) project has come to an end. Set up in...

On June 16h, 2022, P95 turned 11 years old! To everyone who has allowed our company to achieve this milestone, thank...

On the week of  May 16th to May 20th, some of the Epidemiology and Medical Writing team leads met the P95 Latina team...

Expanding to a different region is the dream of any growing company. For P95, the opportunity arose last year, when...

08/02/2022 – Three new vaccine companies (Moderna, Novavax and Valneva) have joined the COVIDRIVE consortium and officially become COVIDRIVE partners. Moderna, Novavax and Valneva will further contribute to the assessment of the effectiveness of COVID-19 vaccines in Europe to support the region’s public health response and address the vaccine companies’ regulatory obligations.

With the inclusion of these three newcomers, COVIDRIVE, which brings together public institutions, small and medium-sized enterprises and vaccine companies, has a total of 11 partners.

P95 is one of the nominees for the 2022 edition of Trends Gazelles Flemish Brabant. Trends Gazelles award aims to distinguish the fastest-growing Belgian companies over the past 5 years.

P95 has appointed Henk Hoornaert as Chief Commercial Officer (CCO). After two years of accelerated growth, this appointment will strengthen P95’s structure and improve business development, marking a further step towards a more stable and mature organization.